Pharmaceutical company Eli Lilly has launched its Alzheimer's drug, donanemab, in India, making it available for patients in the country.

New Alzheimer's drugs, including Lecanemab and Donanemab, which were initially met with high hopes, have disappointed in a recent study, showing more risks than benefits.